Manuscripts

Click the category for manuscript reference details:

Population

Agustí A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.

Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184-92.

Albert P, Agustí A, Edwards L, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax. 2012;67(8):701-8.

Agustí A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the GOLD 2011 COPD groups in the ECLIPSE cohort. Eur Respir J. 2013;42(3):636-46.

Miller J, Edwards LD, Agustí A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107(9):1376-84.

Hanson C, Sayles H, Rutten EEPA, et al. The association between dietary intake and phenotypical characteristics of COPD in the ECLIPSE cohort. Chronic Obstr Pulm Dis. 2014;1(1):115-24.

Hersh CP, Make BJ, Lynch DA, et al. Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. BMC Pulm Med. 2014;14(1):164.

Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44(6):1697-700.

Rutten EPA, Spruit MA, McDonald M-LN, et al. Continuous fat-free mass decline in COPD: fact or fiction? Eur Respir J. 2015;46(5):1496-8.

Health Status (SGRQ/FACIT/CES-D)

Hanania NA, Müllerova H, Locantore NW, et al. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med. 2011;183(5):604-11.

Al-Shair K, Muellerova H, Yorke J, et al. Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale. Health Qual Life Outcomes. 2012;10:100.

NEW

Gietema HA, Edwards LD, Coxson HO, et al. Impact of emphysema and airway wall thickness on quality of life in smoking-related COPD. Respir Med. 2013;107(8):1201-9.

NEW

Rutten EP, Calverley PM, Casaburi R, et al. Changes in body composition in patients with chronic obstructive pulmonary disease: do they influence patient-related outcomes? Ann Nutr Metab. 2013;63(3):239-47.

Janssen DJA, Mullerova H, Agustí A, et al. Persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort. Respir Med. 2014;108:1647-54.

Yohannes AM, Müllerova H, Hanania N, et al. Persistence of depressive symptoms in patients with COPD: A 3-year longitudinal follow-up analysis of the ECLIPSE study cohort. Chest. 2014;146:33A. doi:10.1378/chest.1978679.

Agustí A, Rennard S, Edwards LD, et al. Clinical and prognostic heterogeneity of C and D GOLD groups. Eur Respir J. 2015;46:250-4.

Wilke S, Jones PW, Müllerova H, et al. One-year change in health status and subsequent outcomes in COPD. Thorax. 2015;70:420-5.

Exacerbations

Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Eng J Med. 2010;363(12):1128-38.

Crim C, Celli B, Edwards L, et al. Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. Respir Med. 2011;105(7):1069-78.

Donaldson GC, Müllerova H, Locantore N, et al. Factors associated with change in exacerbation frequency in COPD. Respir Res. 2013;14:79.

NEW

Benson VS, Müllerová H, Vestbo J, et al. Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. Respir Med. 2015;109(9):1147-54.

NEW

Müllerova H, Maselli DJ, Locantore N, et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest. 2015;147(4):999-1007.

NEW

Joppa P, Tkacova R, Franssen FM, et al. Sarcopenic obesity, functional outcomes, and systemic inflammation in patients with chronic obstructive pulmonary disease. J Am Med Dir Assoc. 2016;17(8):712-8.

NEW

Yohannes AM, Mülerová H, Lavoie K, et al. The association of depressive symptoms with rates of acute exacerbations in patients with COPD: results from a 3-year longitudinal follow-up of the ECLIPSE cohort. J Am Med Dir Assoc. 2017;18(11):955-9.

Exercise Tolerance and Activity

Spruit MA, Watkins ML, Edwards LD, et al. Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respir Med. 2010;104(6):849-57.

Polkey MI, Spruit MA, Edwards LD, et al. Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med. 2012;187(4):382-6.

Spruit MA, Polkey MI, Celli B, et al. Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. J Am Med Dir Assoc. 2012;13(3):291-7.

Waschki B, Spruit MA, Watz H, et al. Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med. 2012;106(4):522-30.

NEW

Polkey MI, Spruit MA, Wouters E, et al. Reply: minimal or maximal clinically important difference: using death to define MCID. Am J Respir Crit Care Med. 2013;187(12):1392.

Sumner H, Woodcock A, Kolsum U, et al. Predictors of objective cough frequency in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(9):943-9.

Andrianopolous V, Wouters EFM, Pinto-Planta V, et al. Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. Respir Med. 2015;109:1138-46.

NEW

Andrianopoulos V, Celli BR, Franssen FM, et al. Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study. Respir Med. 2016;119:87-95.

Genomics

Cho MH, Boutaoui N, Klanderman BA, et al. Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet. 2010;42(3):200-2.

Foreman MG, Kong X, DeMeo DL, et al. Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2010;44(3):316-22.

Pillai SG, Kong X, Edwards LD, et al. Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182(12):1498-505.

Wan ES, Cho MH, Boutaoui N, et al. Genome-wide association analysis of body mass in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2010;45(2):304-10.

Brehm JA, Hagiwara LK, Tesfaigzi Y, et al. Identification of FGF7 as a novel susceptibility locus for chronic obstructive pulmonary disease. Thorax. 2011;66(12):1085-90.

Castaldi PJ, Cho MH, Litonjua AA, et al. The association of genome-wide significant spirometric loci with chronic obstructive pulmonary disease susceptibility. Am J Respir Cell Mol Biol. 2011;45(6):1147-53.

Kong X, Cho MH, Anderson WH, et al. Genome-wide association study identifies BICD1 as a susceptibility gene for emphysema. Am J Respir Crit Care Med. 2011;183(1):43-9.

Lipman P, Cho M, Bakke P, et al. On the follow-up of genome-wide association studies: an overall test for the most promising SNPs. Genet Epidemiol. 2011;35(5):303-09.

Qiu W, Cho MH, Riley JH, et al. Genetics of sputum gene expression in chronic obstructive pulmonary disease. PLoS One. 2011;6(9):e24395.

NEW

Siedlinski M, Cho MH, Bakke P, et al. Genome-wide association study of smoking behaviours in patients with COPD. Thorax. 2011;66(10):894-902.

Singh D, Fox SM, Tal-Singer R, et al. Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers. Thorax. 2011;66(6):489-95.

Aminuddin F, Akhabir L, Stefanowicz D, et al. Genetic association between human chitinases and lung function in COPD. Hum Genet. 2012;131(7):1105-14.

Cho MH, Castaldi PJ, Wan ES, et al. A genome-wide association study in COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet. 2012;21(4):947-57.

Kim DK, Cho MH, Hersh CP, et al. Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(12):1238-47.

Wilk JB, Shrine NR, Loehr LR, et al. Genome wide association studies identify CHRNA5/3 and HTR4 in the development of airflow obstruction. Am J Respir Crit Care Med. 2012;186(7):622-32.

Aminuddin F, Hackett TL, Stefanowicz D, et al. Nitric oxide synthase polymorphisms, gene expression and lung function in chronic obstructive pulmonary disease. BMC Pulm Med. 2013;13(1):64.

Hansel NN, Ruczinski I, Rafaels N, et al. Genome-wide study identifies two loci associated with lung function decline in mild to moderate COPD. Hum Genet. 2013;132(1):79-90.

Siedlinski M, Tingley D, Lipman PJ, et al. Dissecting direct and indirect genetic effects on chronic obstructive pulmonary disease (COPD) susceptibility. Hum Genet. 2013;132(4):431-41.

Zhou X, Qiu W, Sathirapongsasutil JF, et al. Gene expression analysis uncovers novel Hedgehog interacting protein (HHIP) effects in human bronchial epithelial cells. Genomics. 2013;101(5):263-72.

Cho MH, McDonald ML, Zhou X, et al. Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis. Lancet Respir Med. 2014;2(3):214-25.

Glass K, Quackenbush J, Silverman EK, et al. Sexually-dimorphic targeting of functionally-related genes in COPD. BMC Syst Biol. 2014;8(1):118.

NEW

Lee JH, Cho MH, Hersh CP, et al. Genetic susceptibility for chronic bronchitis in chronic obstructive pulmonary disease. Respir Res. 2014;15(1):113.

McDonald M-L, Cho M, Sorheim I-C, et al. Common genetic variants associated with resting oxygenation in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2014;51(5):678-87.

McDonald ML, Mattheisen M, Cho MH, et al. Beyond GWAS in COPD: probing the landscape between gene-set associations, genome-wide associations and protein-protein interaction networks. Hum Hered. 2014;78(3):131-9.

Menche J, Sharma A, Cho MH, et al. A diVIsive Shuffling Approach (VIStA) for gene expression analysis to identify subtypes in chronic obstructive pulmonary disease. BMC Syst Biol. 2014;8(Suppl 2):S8.

Singh D, Fox SM, Tal-Singer R, et al. Altered gene expression in blood and sputum in COPD frequent exacerbators in the ECLIPSE Cohort. PLoS ONE. 2014;29(9):e107381.

Castaldi PJ, Cho MH, Zhou X, et al. Genetic control of gene expression at novel and established chronic obstructive pulmonary disease loci. Hum Mol Genet. 2015;24(4):1200-10.

Dijksta AE, Boezen HM, van den Berge M, et al. Dissecting genetic risk factors for chronic mucus hypersecretion in heavy smokers with and without COPD. Eur Respir J. 2015;45(1):60-75.

Lee JH, Cho MH, Hersh CP, et al. IREB2 and GALC are associated with pulmonary artery enlargement in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2015;52(3):365-76.

NEW

Chang Y, Glass K, Liu YY, et al. COPD subtypes identified by network-based clustering of blood gene expression. Genomics. 2016;107(2):51-8.

NEW

Obeidat ME, Ding X, Fishbane N, et al. The effect of different case definitions of current smoking on the discovery of smoking-related blood gene expression signatures in chronic obstructive pulmonary disease. Nicotine Tob Res. 2016;18(9):1903-9.

NEW

Busch R, Hobbs BD, Zhou J, et al. Genetic association and risk scores in a chronic obstructive pulmonary disease meta-analysis of 16,707 subjects. Am J Respir Cell Mol Biol. 2017;57(1):35-46.

NEW

Hobbs BD, De Jong K, Lamontagne M, et al. Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. Nat Genet. 2017;49(3):426-32.

Imaging

Basanta M, Jarvis RM, Xu Y, et al. Non-invasive metabolomic analysis of breath using differential mobility spectrometry in patients with chronic obstructive pulmonary disease and healthy smokers. Analyst. 2010;135(2):315-20.

Gietema HA, Müller NL, Fauerbach PV, et al. Quantifying the extent of emphysema: factors associated with radiologists' estimations and quantitative indices of emphysema severity using the ECLIPSE cohort. Acad Radiol. 2011;18(6):661-71.

Coxson H, Dirksen A, Edwards L, et al. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respir Med. 2013;1(2):129-36.

Romme EA, Murchison JT, Edwards LD, et al. CT-measured bone attenuation in patients with chronic obstructive pulmonary disease: relation to clinical features and outcomes. J Bone Miner Res. 2013;28(6):1369-77.

McDonald ML, Diaz AA, Ross JC, et al. Quantitative computed tomographic measures of pectoralis muscle area and disease severity in chronic obstructive pulmonary disease: a cross-sectional study. Ann Am Thorac Soc. 2014;11(3):326-34.

Cho MH, Castaldi PJ, Hersh CP, et al. A genome-wide association study of emphysema and airway quantitative imaging phenotypes. Am J Respir Crit Care Med. 2015;192:559-69.

Thomsen LH, Shaker SB, Dirksen A, et al. Correlation between emphysema and lung function in healthy smokers and smokers with COPD. J COPD F. 2015;2(3):204-13.

Biomarkers

Lomas DA, Silverman EK, Edwards LD, et al. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax. 2008;63(12);1058-63.

Lomas DA, Silverman EK, Edwards LD, et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J. 2009;34(1):95-102.

Singh D, Edwards L, Tal-Singer R, et al. Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res. 2010;11:77.

Dickens JA, Miller BE, Edwards LD, et al. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res. 2011;12:146.

NEW

Duvoix A, Miller B, Tal-Singer R, et al. The development of biomarkers for chronic obstructive pulmonary disease: the ECLIPSE study. Clin Lab Intl. 2011.

Duvoix A, Miranda E, Perez J, et al. Evaluation of full-length, cleaved and nitrosylated serum surfactant protein D as biomarkers for COPD. COPD. 2011;8(2):79-95.

Esther CR Jr, Lazaar AL, Bordonali E, et al. Elevated airway purines in COPD. Chest. 2011;140(4):954-60.

MacNee W, Rennard SI, Hunt JF, et al. Evaluation of exhaled breath condensate pH as a biomarker for COPD. Respir Med. 2011;105(7):1037-45.

Sin DD, Miller B, Duvoix A, et al. Serum PARC/CCL-18 concentrations and health outcomes in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2011;183(9):1187-92.

Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483.

Breyer MK, Rutten E, Locantore N, et al. Dysregulated adipokine metabolism in chronic obstructive pulmonary disease. Eur J Clin Invest. 2012;42(9):983-91.

Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(10):1065-72. 

Ubhi BK, Cheng KK, Dong J, et al. Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. Mol Biosyst. 2012;8(12):3125-33.

Ubhi BK, Riley JH, Shaw PA, et al. Metabolic profiling detects biomarkers of protein degradation in COPD patients. Eur Respir J. 2012;40(2):345-55.

Berg I, Hanson C, Sayles H, et al. Vitamin D, Vitamin D Binding Protein, Lung Function and Structure in COPD. Respir Med. 2013;107(10):1578-88.

Cheng D, Kim D, Cockayne D, et al. Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(8):948-5.

Lazaar AL, Miller BE, Francombe G, et al. No TWEAK for COPD. Eur Respir J. 2013;42:1142-44.

Rutten EPA, Calverley PMA, Casuburi R, et al. Changes in body composition in patients with chronic obstructive pulmonary disease; do they influence patient related outcomes? Ann Nutr Metab. 2013;63(3):239-47.

NEW

Sumner H, Woodcock A, Kolsum U, et al. Predictors of objective cough frequency in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(9):943-9.

Diaz AA, Zhou L, Young TP, et al. Chest CT measures of muscle and adipose tissue in COPD: gender-based differences in content and in relationships with blood biomarkers. Acad Radiol. 2014;21(10):1255-61.

Johansson SL, Roberts NB, Schlosser A, et al. Microfibrillar-associated protein 4: a potential biomarker of chronic obstructive pulmonary disease. Respir Med. 2014;108(9):1336-44.

Lee JH, Cho MH, Hersh CP, et al. IREB2 and GALC are associated with pulmonary artery enlargement in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2014;52:365-76.

Lee JH, McDonald M-LN, Cho MH, et al. DNAH5 is associated with total lung capacity in chronic obstructive pulmonary disease. Resp Res. 2014;15(1):97.

Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44(6);1697-700.

Wells JM, O'Reilly PJ, Szul T, et al. An aberrant leukotriene A4 hydrolase–proline-glycine-proline pathway in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;190(1):51-61.

Williams MC, Murchison JT, Edwards LD, et al. Coronary artery calcification is increased in patients with COPD and associated with morbidity and mortality. Thorax. 2014;69(8):718-23.

NEW

Ongay S, Sikma M, Horvatovich P, et al. Free urinary desmosine and isodesmosine as COPD biomarkers: the relevance of confounding factors. Chronic Obstr Pulm Dis. 2016;3(2):560-9.

NEW

Rabinovich RA, Miller BE, Wrobel K, et al. Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. Eur Respir J. 2016;47(5):1365-73.

NEW

Sand JM, Leeming DJ, Byrjalsen I, et al. High levels of biomarkers of collagen remodelling are associated with increased mortality in COPD-results from the ECLIPSE study. Respir Res. 2016;17(1):125.

NEW

Leeming DJ, Byrjalsen I, Sand JM, et al. Biomarkers of collagen turnover are related to annual change in FEV 1 in patients with chronic obstructive pulmonary disease within the ECLIPSE study. BMC Pulm Med. 2017;17(1):164.

Protocol

Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J. 2008;31(4):869-73.

NEW

Yohannes AM, Müllerová H, Hanania NA, et al. Long-term course of depression trajectories in patients with COPD: a 3-year follow-up analysis of the evaluation of COPD longitudinally to identify predictive surrogate endpoints cohort. Chest. 2016;149(4):916-26.

Reviews

Faner R, Tal-Singer R, Riley JH, et al. Lessons from ECLIPSE: a review of COPD biomarkers. Thorax. 2014;69(7):666-72.

Vestbo J, Agusti A, Wouters EFM, et al. Should we view COPD differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med. 2014;189(9):1022-30.

NEW

Huang JT, Bolton CE, Miller BE, et al. Age-dependent elastin degradation is enhanced in chronic obstructive pulmonary disease. Eur Respir J. 2016;48(4):1215-8.

NEW

Papi A, Magnoni MS, Muzzio CC, et al. Phenomenology of COPD: interpreting phenotypes with the ECLIPSE study. Monaldi Arch Chest Dis. 2016;83(1-2):721.

Systems Biology

Chu J-H, Hersh C, Castaldi P, et al. Analyzing networks of phenotypes in complex diseases: methodology and applications in COPD. BMC Syst Biol. 2014;8(1):78.

Rennard SI, Locantore N, Delafont B, et al. Identification of five COPD subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc. 2015;12(3):303-12.

NEW

González G, Ash SY, Vegas-Sánchez-Ferrero G, et al. Disease staging and prognosis in smokers using deep learning in chest computed tomography. Am J Respir Crit Care Med. 2018;197(2):193-203.